Retina/Vitreous News

In this Healio Video Perspective from the ASRS meeting, Jordana G. Fein, MD, MS, of Retina Group of Washington discusses IOP outcomes in patients with diabetic macular edema who were treated with aflibercept 8 mg or aflibercept 2 mg.

Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.

Optometry in the 21st century has moved strongly toward evidence-based medicine, with the American Optometric Association even publishing a 14-step process to assist in the development of an evidence-based practice.

Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases when delivered as a combination therapy vs. anti-VEGF-A monotherapies, according to a study.

In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.

In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

A form of dropless vitrectomy helped control intraocular inflammation and prevent infection after surgery for vitreous hemorrhage secondary to proliferative diabetic retinopathy, according to a study.

In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.

Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.